Tower Research Capital (TRC)’s NeuroSense Therapeutics NRSN Stock Holding History

Tower Research Capital (TRC)’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-490	Closed	-$33K	–	6346
2022 Q2	$33K	Buy	490 +475	+3,167%	+$18K	﹤0.01%	3277
2022 Q1	$1K	Sell	15 -51	-77%	-$2.43K	﹤0.01%	5830
2021 Q4	$3K	Buy	+66	New	+$4.01K	﹤0.01%	5471

Other funds holding NRSN

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Tower Research Capital (TRC)'s NRSN Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of NeuroSense Therapeutics (NRSN) in Q3 2022, closing a stake of 490 shares — an estimated $33K sold.

Tower Research Capital (TRC) first reported a position in NRSN in Q4 2021 and held it in 3 quarters. The position peaked at $33K in Q2 2022. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2022.

Tower Research Capital (TRC) reported no remaining NeuroSense Therapeutics position as of Q3 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 490 NeuroSense Therapeutics shares in Q3 2022, an estimated $33K.
Tower Research Capital (TRC) first reported a position in NeuroSense Therapeutics in Q4 2021 and held it in 3 quarters.
Tower Research Capital (TRC)'s NeuroSense Therapeutics position peaked at $33K in Q2 2022.
4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.